Search Result

Results for "

uremic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Apoptosis (1) Aryl Hydrocarbon Receptor (1) Bacterial (1) Bcl-2 Family (1) Complement System (9) Cytochrome P450 (1) Drug Metabolite (1) Endogenous Metabolite (10) Fluorescent Dye (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (4) OAT (1) P-glycoprotein (1) p38 MAPK (4) PARP (2) Reactive Oxygen Species (ROS) (3) Reference Standards (3) Thyroid Hormone Receptor (1) Toll-like Receptor (TLR) (1) UGT (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (10) Metabolic Disease (14) Neurological Disease (1)

By Targets:

11β-HSD (1)

Apoptosis (1)

Aryl Hydrocarbon Receptor (1)

Bacterial (1)

Bcl-2 Family (1)

Complement System (9)

Cytochrome P450 (1)

Drug Metabolite (1)

Endogenous Metabolite (10)

Fluorescent Dye (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JNK (4)

OAT (1)

P-glycoprotein (1)

p38 MAPK (4)

PARP (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (3)

Thyroid Hormone Receptor (1)

Toll-like Receptor (TLR) (1)

UGT (1)

By Research Areas:

Cancer (1)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (10)

Metabolic Disease (14)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-127105

Iptacopan Maximum Cited Publications 13 Publications Verification LNP023	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

HY-111431

p-Cresyl sulfate Maximum Cited Publications 6 Publications Verification p-Tolyl sulfate	JNK p38 MAPK Reactive Oxygen Species (ROS)	Metabolic Disease
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .

HY-111431A

p-Cresyl sulfate potassium Maximum Cited Publications 6 Publications Verification p-Tolyl sulfate potassium	Endogenous Metabolite JNK p38 MAPK	Metabolic Disease Inflammation/Immunology
p-Cresyl sulfate potassium is a uremic toxin that binds to a prototype protein. p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways. p-Cresyl sulfate potassium has pro-inflammatory activity .

HY-117930

Danicopan 4 Publications Verification ACH-4471	Complement System	Inflammation/Immunology
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with K_d value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .

HY-W011910

Potassium 1H-indol-3-yl sulfate 1 Publications Verification	Endogenous Metabolite Aryl Hydrocarbon Receptor Cytochrome P450 UGT Interleukin Related	Metabolic Disease
Potassium 1H-indol-3-yl sulfate is a metabolite of tryptophan, produced by intestinal microorganisms and combined with sulfate in the liver before entering the circulatory system. Potassium 1H-indol-3-yl sulfate is a potent endogenous agonist of the aryl hydrocarbon receptor (AhR) and a urinary toxin. Potassium 1H-indol-3-yl sulfate can be used for research on kidney diseases .

HY-127105A

Iptacopan hydrochloride Maximum Cited Publications 13 Publications Verification LNP023 hydrochloride	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

HY-113432

Nudifloramide 2PY	Endogenous Metabolite PARP	Metabolic Disease
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-W014130

N-Acetyl-L-arginine 1 Publications Verification Ac-Arg-OH	Endogenous Metabolite	Others
N-Acetyl-L-arginine (Ac-Arg-OH) is one of the guanidino compounds found elevated in the serum of a hemodialyzed renal insufficient (uremic) pediatric population. N-Acetyl-L-arginine shows synergistic activity with glycine buffer. N-Acetyl-L-arginine suppresses the aggregation of intravenous immunoglobulins with a minimum decrease in transition temperature. N-Acetyl-L-arginine dramatically reduces IL-1 expression in the presence of silicone oil. N-Acetyl-L-arginine also demonstrates colloidal stability .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-122009

Indican Indoxyl-β-D-glucoside	P-glycoprotein OAT Fluorescent Dye	Others
Indican (Indoxyl-β-D-glucoside), a glycoside of indoxyl, is a precursor of the dyesindigo and indirubin. Indican has a major metabolite, indoxyl sulfate (IS). IS, an uremic toxin, is a substrate/inhibitor of organic anion transporter (OAT) 1, OAT 3 and multidrug resistance-associated protein (MRP) 4 .

HY-P99050

Sutimlimab BIVV009; IPN-009; TNT009	Complement System	Cardiovascular Disease Inflammation/Immunology
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .

HY-P4823

pTH (1-37) (human)	Thyroid Hormone Receptor	Metabolic Disease
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .

HY-128342

Complement C5-IN-1 1 Publications Verification	Complement System	Inflammation/Immunology
Compound C5-IN-1 (Compound 7) is a selective allosteric inhibitor of complement component protein C5. Compound C5-IN-1 prevents C5 from being cleaved by C5 convertase, inhibits the cleavage of C5 into C5a and C5b, and thus blocks the formation of membrane attack complex (MAC). Compound C5-IN-1 has an IC₅₀ of 0.77 μM and 5 nM in 50% human whole blood and 2% human serum to block MAC deposition induced by zymosan, respectively. Compound C5-IN-1 can be used to study diseases related to complement overactivation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .

HY-111431AS

p-Cresol sulfate-d7 potassium p-Tolyl sulfate-d7 potassium	Endogenous Metabolite	Metabolic Disease
p-Cresol sulfate-d₇ (potassium) is the deuterium labeled p-Cresyl sulfate potassium. p-Methylphenyl potassium sulfate is a prototype protein-bound uremic toxin[1][2].

HY-W416250

p-Cresol glucuronide	Drug Metabolite	Cardiovascular Disease
p-Cresol glucuronide, a metabolite of p-cresol, is a prototype protein-bound uremic toxin. p-Cresol glucuronide is associated with chronic kidney disease (CKD) .

HY-W674241A

4-Ethylphenyl sulfate sodium	Endogenous Metabolite Apoptosis Bcl-2 Family Reactive Oxygen Species (ROS)	Neurological Disease Cancer
4-Ethylphenyl sulfate sodium is an orally active and brain-penetrant gut microbial metabolite. 4-Ethylphenyl sulfate sodium downregulates Bcl2 expression, upregulates Bax expression, and induces cancer cell apoptosis via the endogenous apoptotic pathway. 4-Ethylphenyl sulfate sodium induces G2/M cell cycle arrest and reactive oxygen species (ROS) production. 4-Ethylphenyl sulfate sodium impairs oligodendrocyte maturation, reduces oligodendrocyte-neuron interactions, decreases axonal myelination levels, and shifts the oligodendrocyte population toward immature precursor cells. 4-Ethylphenyl sulfate sodium alters brain region-specific neural activity and functional connectivity in mice, and correlates with anxiety-like behaviors in mice .

HY-113432R

Nudifloramide (Standard) 2PY (Standard)	Reference Standards Endogenous Metabolite PARP	Metabolic Disease
Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-111431AR

p-Cresyl sulfate potassium (Standard) p-Tolyl sulfate potassium (Standard)	JNK p38 MAPK Reactive Oxygen Species (ROS) Reference Standards	Metabolic Disease
p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways .

HY-W014130R

N-Acetyl-L-arginine (Standard) Ac-Arg-OH (Standard)	Reference Standards Endogenous Metabolite	Others
N-Acetyl-L-arginine (Ac-Arg-OH) is one of the guanidino compounds found elevated in the serum of a hemodialyzed renal insufficient (uremic) pediatric population. N-Acetyl-L-arginine shows synergistic activity with glycine buffer. N-Acetyl-L-arginine suppresses the aggregation of intravenous immunoglobulins with a minimum decrease in transition temperature. N-Acetyl-L-arginine dramatically reduces IL-1 expression in the presence of silicone oil. N-Acetyl-L-arginine also demonstrates colloidal stability .

HY-200854

Iptacopan hydrochloride hydrate LNP023 hydrochloride hydrate	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

HY-W019720

1-Methylguanidine hydrochloride	Endogenous Metabolite	Inflammation/Immunology
1-Methylguanidine hydrochloride is a uremic toxin, which accumulate in dogs with renal failure and chronic kidney disese. 1-Methylguanidine hydrochloride enhances the oxidative metabolism and induces apoptosis in neutrophils .

HY-W654121

p-Cresol sulfate-d4 potassium p-Tolyl sulfate-d4 potassium	Isotope-Labeled Compounds Endogenous Metabolite p38 MAPK JNK	Inflammation/Immunology
p-Cresol sulfate-d₄ (potassium) is deuterium labeled p-Cresyl sulfate (potassium). p-Cresyl sulfate potassium is a uremic toxin that binds to a prototype protein. p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways. p-Cresyl sulfate potassium has pro-inflammatory activity .

HY-P11232

NAB815	Toll-like Receptor (TLR) Bacterial	Infection
NAB815 is a specific inhibitor of the Stx2a (K_d = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC₅₀ = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS) .

HY-180415

UE2316	11β-HSD	Metabolic Disease
UE2316 is an orally active and specific 11βHSD1 inhibitor. UE2316 significantly improves glucose tolerance and insulin sensitivity in uremic rats. UE2316 also exacerbates hepatic fibrosis in mice. UE2316 can be used in the research of diseases such as hepatic fibrosis, uremia and diabetes mellitus .

HY-P991022

Ruxoprubart NM8074	Complement System	Endocrinology
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy .

HY-127105B

Iptacopan TFA LNP023 TFA	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

Cat. No.	Product Name	Target	Research Area